INCY250516P40000
- 0.00
- 0.000.00%
Incyte Newsroom
Earnings Call Summary | Incyte(INCY.US) Q1 2025 Earnings Conference
9 Analysts Have This To Say About Incyte
TD Cowen Lowers Price Target on Incyte to $86 From $88
Incyte Price Target Raised to $59.00/Share From $58.00 by Wells Fargo
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $59
Incyte Is Maintained at Sector Perform by RBC Capital
Morgan Stanley Adjusts Incyte's Price Target to $68 From $65
Incyte Analyst Ratings
RBC Raises Price Target on Incyte to $67 From $64, Keeps Sector Perform Rating
Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Incyte (INCY) and Verona Pharma (VRNA)
Incyte's Growth Prospects Hindered by Jakafi's Exclusivity Loss and Strategic Limitations
Express News | Incyte : Stifel Cuts Target Price to $75 From $77
Incyte's Q1 2025 Earnings: Strong Growth and Optimism
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $89
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $86
Incyte's Promising Growth Potential and Strategic Positioning Amidst Market Challenges
Incyte | 10-Q: Q1 2025 Earnings Report
Research Alert: CFRA Maintains Buy View On Shares Of Incyte Corporation
Wells Fargo Hikes Price Target on Incyte to $59 From $58
Jefferies Adjusts Incyte Price Target to $76 From $75